Translational Research Symposium Speaker Spotlight: Professor Eva Segelov

Professor Eva Segelov

Monash University's 3rd annual Translational Research Symposium is being hosted by its three metropolitan clinical schools on 31 July 2017. The symposium will host a diverse group of medical researchers presenting their work into translational research. RSVP here.

Professor Eva Segelov is the Professor/Director Oncology School of Clinical Sciences and Monash Health.

Professor Segelov will be discussing the role of aspirin in modulating response to cancer. Abstract:
-----------------------------

The two main aspects of aspirin in cancer are prevention of primary and secondary cancer; and modulation of the immune response to cancer. Aspirin has been shown in large cohort and population-based studies to prevent a variety of cancers (primary prevention) and additionally to prevent recurrence, including for bowel, prostate and breast cancer. The ‘gold standard’ randomized controlled Phase III trials comparing aspirin with placebo are underway in multiple tumour types. The mechanism of action is not fully described but is likely to relate to immune modulation rather than antithrombotic effect. There are putative predictive biomarkers, at least for some cancers such as colorectal cancer.  In addition, aspirin holds promise for patients with in situ cancers as an immune modulator which may enhance response particularly of radiotherapy as well as modern immune-oncology agents.

-----------------------------

We look forward to welcoming Professor Segelov for the Symposium!

More information:
Translational Research Symposium

• Date: Monday 31 July, 2017
• Time: 8:30 for 9:00am start - 7:00pm close
• RSVP here

Find out more about the symposium and our speaker program.